Fubitai Vaccine | Pfizer: Experiments show that 3 doses of COVID-19 vaccine effectively neutralize Omicron

American pharmaceutical company Pfizer (Pfizer) and German biotech company (BioNTech) said on December 8 that laboratory tests showed that 3 doses of the new coronavirus pneumonia (COVID-19) vaccine jointly developed by them can effectively neutralize Variant virus strain Omicron (Omi Keron).

Pfizer and BioNTech issued a statement saying that 3 doses of the new crown vaccine they developed can increase the level of neutralizing antibodies against Omicron in the serum by 25 times.

Tests have shown that the serum provided by the person who received the third dose of the vaccine one month ago effectively neutralized Omicron, and its efficacy was similar to that of the serum from the person who had received the two doses of the vaccine against the original virus strain.

New crown pneumonia outbreak in the UK: The picture shows the British government setting up a temporary new crown vaccination center in a fire station in Belfast on December 4.

(Reuters)

The new coronavirus relies on "Spike protein" to bind to receptors on human cell membranes to invade human cells.

Neutralizing antibodies can prevent them from binding, thereby preventing the virus from invading.

Pfizer and BioNTech stated that they will continue to develop a vaccine against Omicron, and if necessary, they can launch this vaccine in March 2022.

Pharmaceutical factory: GSK anti-coronary pneumonia drug is effective for all Omicron mutations. Omicron has discovered an invisible version. PCR rapid screening is difficult to identify. Research instructions are concerned about Omicron | Research: New variants can partially evade Pfizer vaccine protection and reduce antibody levels. Omicron | South Africa Severe Case Comparison Is less enough to take a sigh of relief?

The unusual thing is worrying

"Pfizer Vaccine" is jointly developed by Pfizer and BioNTech.

The commercial Chinese name of this vaccine called BNT162b2 in mainland China, Hong Kong and Macau is "Fubitai", and its introduction and commercialization are undertaken by BioNTech's partner Fosun Pharma.